The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the ...

A study published in July 2025 issue of Journal of Allergy and Clinical Immunology Global highlighted persistent challenges and fragmented care in managing individuals with severe asthma with an ...

Sputum IL-8 levels are significantly higher in non-eosinophilic asthma patients than in eosinophilic phenotypes and healthy controls.

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

TSLP inhibitor Tezspire clinically has validated Thymic Stromal LymphoPoietin (TSLP) as a valid target for treatment of inflammatory diseases by its approval in late 2021 in the US and in 2022 in ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – ...

Eosinophilic gastrointestinal diseases are exponentially more prevalent among patients with atopic diseases compared with the ...

Primary care physicians play a vital role in identifying red flags for rare eosinophilic diseases like HES and EGPA, enabling ...

The latest UK asthma guidelines1 clearly define the role of Fractional exhaled Nitric Oxide (FeNO) testing in both diagnosing ...

Internationally recognized allergist, researcher, and scholar joins nation’s leading asthma and allergy advocacy organization ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best hot stocks to buy according to Wall Street analysts.